User profiles for J Capdevila

Joan Capdevila Pujol

Universitat Politècnica de Catalunya
Verified email at ac.upc.edu
Cited by 6692

[HTML][HTML] Cytochrome P450 and arachidonic acid bioactivation: molecular and functional properties of the arachidonate monooxygenase

JH Capdevila, JR Falck, RC Harris - Journal of lipid research, 2000 - ASBMB
The demonstration of in vivo arachidonic acid epoxidation and ω-hydroxylation established
the cytochrome P450 epoxygenase and ω/ω–1 hydroxylase as formal metabolic pathways …

[HTML][HTML] Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical …

…, WD Travis, D Bartsch, J Capdevila, F Costa, J Cwikla… - Annals of …, 2015 - Elsevier
Background Pulmonary carcinoids (PCs) are rare tumors. As there is a paucity of randomized
studies, this expert consensus document represents an initiative by the European …

[HTML][HTML] Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National …

R Garcia-Carbonero, J Capdevila, G Crespo-Herrero… - Annals of oncology, 2010 - Elsevier
Background Neuroendocrine tumors (NETs) are an unusual family of neoplasms with a wide
and complex spectrum of clinical behavior. Here, we present the first report of a National …

[HTML][HTML] Risk of COVID-19 among front-line health-care workers and the general community: a prospective cohort study

…, JW Rich-Edwards, R Davies, J Capdevila… - The Lancet Public …, 2020 - thelancet.com
Background Data for front-line health-care workers and risk of COVID-19 are limited. We
sought to assess risk of COVID-19 among front-line health-care workers compared with the …

[HTML][HTML] Everolimus for advanced pancreatic neuroendocrine tumors

…, TJ Hobday, T Okusaka, J Capdevila… - … England Journal of …, 2011 - Mass Medical Soc
Background Everolimus, an oral inhibitor of mammalian target of rapamycin (mTOR), has
shown antitumor activity in patients with advanced pancreatic neuroendocrine tumors, in two …

[HTML][HTML] Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study

…, K Klaser, A May, L Polidori, J Capdevila… - The Lancet Infectious …, 2021 - thelancet.com
Background The Pfizer-BioNTech (BNT162b2) and the Oxford-AstraZeneca (ChAdOx1
nCoV-19) COVID-19 vaccines have shown excellent safety and efficacy in phase 3 trials. We …

[HTML][HTML] Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance …

…, CH Sudre, B Fox, A Hammers, J Wolf, J Capdevila… - The Lancet, 2022 - thelancet.com
Background The SARS-CoV-2 variant of concern, omicron, appears to be less severe than
delta. We aim to quantify the differences in symptom prevalence, risk of hospital admission, …

[HTML][HTML] Lanreotide in metastatic enteropancreatic neuroendocrine tumors

…, G Cadiot, EM Wolin, J Capdevila… - … England Journal of …, 2014 - Mass Medical Soc
Background Somatostatin analogues are commonly used to treat symptoms associated with
hormone hypersecretion in neuroendocrine tumors; however, data on their antitumor effects …

Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant …

…, T Fokstuen, AJ Ten Tije, J Capdevila… - The Lancet …, 2021 - thelancet.com
Background Systemic relapses remain a major problem in locally advanced rectal cancer.
Using short-course radiotherapy followed by chemotherapy and delayed surgery, the Rectal …

ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine …

…, B Eriksson, G Kaltsas, DK Bartsch, J Capdevila… - …, 2016 - karger.com
Only advances that occurred from 2011 to 2014 that either strengthen the previous 2011
guidelines [1, 2] or lead to changes or additional guidelines are reviewed here. Advances and …